The Application of Ursodeoxycholic Acid for the Prevention of SARS-CoV-2 Infection (COVID-19)

Study of ABT-333 in Both Healthy Volunteers and Hepatitis C Virus (HCV) + Genotype 1 Infected Subjects

NCT00696904 ·Status: COMPLETED ·Phase: PHASE1

A Trial to Evaluate Safety, Tolerability, PK and Antiviral Activity of MB-110 in Hepatitis C Virus Infected Patients

NCT02617615 ·Status: UNKNOWN ·Phase: PHASE1

A Single Ascending Dose Study of BMS-650032 in HCV Infected Subjects

NCT00559247 ·Status: COMPLETED ·Phase: PHASE1/PHASE2

Safety, Tolerability, Pharmacokinetics (PK) and Pharmacodynamics (PD) of SH229 in Patients With HCV Infection

NCT03588923 ·Status: COMPLETED ·Phase: PHASE1

Evaluating the Safety of ITX 5061 in Treatment-Naive Hepatitis C (HCV)-Infected Adults

NCT01165359 ·Status: COMPLETED ·Phase: PHASE1

Study to Evaluate Drug-drug Interaction Between Valopicitabine and Ribavirin

NCT00395421 ·Status: COMPLETED ·Phase: PHASE2

Effectiveness, Safety and Clinical Outcomes of Paritaprevir/Ombitasvir/r+Dasabuvir 8 Weeks

NCT03122132 ·Status: COMPLETED

Study to Determine the Safety and Effectiveness of Antiviral Combination Therapy to Treat Hepatitis C Virus (HCV) in Patients Who Have Previously Not Received the Standard of Care

NCT01359644 ·Status: COMPLETED ·Phase: PHASE2

Study to Assess the Safety, Tolerability, Pharmacokinetics and Antiviral Activity of ABT-267 in HCV Infected Subjects

NCT01563536 ·Status: COMPLETED ·Phase: PHASE2

Eltrombopag To Initiate And Maintain Interferon Antiviral Treatment To Benefit Subjects With Hepatitis C Liver Disease

NCT00529568 ·Status: COMPLETED ·Phase: PHASE3

A Study to Assess the Safety, Tolerability, and Pharmacokinetics of Multiple Ascending Doses of the ABT-333 Tablet

NCT00909636 ·Status: COMPLETED ·Phase: PHASE1

Safety and Efficacy of Albumin Interferon Administered Every 4 Weeks in Genotype 2/3 Hepatitis C Patients

NCT00759200 ·Status: COMPLETED ·Phase: PHASE2

Study of Nitazoxanide in the Treatment of Chronic Hepatitis C

NCT00418639 ·Status: COMPLETED ·Phase: PHASE2

Safety, Tolerability, Pharmacokinetics and Antiviral Activity of GS-9669 in Subjects With Chronic Hepatitis C Virus Infection

NCT01431898 ·Status: COMPLETED ·Phase: PHASE1

Study of ABT-267 in Both Healthy Volunteers and Hepatitis C Virus (HCV) Genotype 1 Infected Subjects

NCT01181427 ·Status: COMPLETED ·Phase: PHASE1

A Study to Evaluate the Combination of Pegylated Interferon Alfa Plus Valopicitabine in Patients With Hepatitis C

NCT00118768 ·Status: COMPLETED ·Phase: PHASE2

A Study of Single Dose of ABT-333 in Healthy Male Adults

NCT00919490 ·Status: COMPLETED ·Phase: PHASE1

A Two Week Dosing Study to Determine the Safety and Antiviral Activity of LCQ908 in Hepatitis C Patients

NCT01387958 ·Status: TERMINATED ·Phase: PHASE2

A Study of Faldaprevir, Ribavirin and TD-6450 in Participants With Genotype 4 Hepatitis C Virus Infection

NCT02593162 ·Status: COMPLETED ·Phase: PHASE2

Multiple Oral Doses of BI 207127 NA in Treatment naïve and Treatment-experienced Hepatitis C Virus (HCV)-Infected Patients

NCT02176525 ·Status: COMPLETED ·Phase: PHASE1

Safety Study of Pegylated Interferon Lambda Plus Single or 2 Direct Antiviral Agents With Ribavirin

NCT01309932 ·Status: COMPLETED ·Phase: PHASE2

A Follow-up Assessment of Resistance to ABT-333 in Hepatitis C Virus (HCV)-Infected Subjects Who Have Received ABT-333 in ABT-333 Studies

NCT00726882 ·Status: COMPLETED ·Phase: PHASE2

A Study of ABT-072 in Healthy and Hepatitis C Virus Genotype 1-Infected Adults

NCT00752687 ·Status: COMPLETED ·Phase: PHASE1

Study of Hepatitis C Virus (HCV) Nonstructural Protein 5a (NS5A) Inhibitor IDX719 in Healthy and HCV-Infected Participants (MK-1894-001)

NCT01508156 ·Status: COMPLETED ·Phase: PHASE1/PHASE2

Study of Nitazoxanide Combined With Peginterferon Compared to Peginterferon Monotherapy in the Treatment of Hepatitis C

NCT00418054 ·Status: COMPLETED ·Phase: PHASE2